Skip to main content
. 2022 Aug 12;82(1):154–160. doi: 10.1136/ard-2022-222849

Table 1.

Baseline demographics and clinical characteristics of all JIA patients and each JIA category in TP1

Variable JIA (N=86) ERA (N=52) JPsA (N=34)
Age (years), mean (SD) 13.1 (3.1) 13.7 (2.6) 12.2 (3.7)
Male, n (%) 57 (66.3) 41 (78.8) 16 (47.1)
Race, n (%)
 White 82 (95.3) 51 (98.1) 31 (91.2)
 Other* 4 (4.7) 1 (1.9) 3 (8.8)
Ethnicity, n (%)
 Hispanic or Latino 5 (5.8) 2 (3.8) 3 (8.8)
 Caucasian 67 (77.9) 42 (80.8) 25 (73.5)
 Unknown† 14 (16.3) 8 (15.4) 6 (17.6)
JADAS-27 score, mean (SD) 15.1 (7.1) 14.8 (6.7) 15.5 (7.8)
Physician global assessment of disease activity (VAS 0–100 mm), mean (SD) 47.3 (21.1) 47.2 (20.2) 47.4 (22.9)
Parent/patient global assessment of overall well-being (VAS 0–100 mm), mean (SD) 48.5 (28.3) 50.0 (27.6) 46.3 (29.5)
Childhood Health Assessment Questionnaire–Disability Index, mean (SD) 0.8 (0.6) 0.8 (0.6) 0.8 (0.7)
Number of joints with active arthritis, mean (SD) 7.7 (7.5) 6.2 (3.4) 10.0 (10.6)
Number of joints with limited range of motion, mean (SD) 5.5 (4.7) 4.9 (3.3) 6.6 (6.3)
C-reactive protein standardised value (mg/L), mean (SD) 18.6 (32.0) 24.0 (38.8) 10.4 (14.0)
Total enthesitis count, mean (SD) 2.6 (2.5); n=85 2.7 (2.2); n=52 2.3 (3.0); n=33
Total dactylitis count, mean (SD) 1.0 (2.2); n=82 0.4 (1.4); n=48 1.8 (2.7); n=34
MTX use, n (%) yes 56 (65.1) 33 (63.5) 23 (67.6)

*Asian and other races.

†ethnicity not reported or unknown.

ERA, enthesitis-related arthritis; JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; TP, treatment period; VAS, visual analogue scale.